![Jeff Ryckman: How many patients make it to CAR-T without ever seeing radiotherapy?](https://oncodaily.com/pub/uploads/2023/09/Jeff-Ryckman-2-e1704219037424-1280x1070.jpeg)
Jeff Ryckman: How many patients make it to CAR-T without ever seeing radiotherapy?
Jeff Ryckman, Radiation Oncologist and Assistant Professor at West Virginia University shared a post by David Russler-Germain on X/Twitter, adding:
”How many patients make it to CAR-T without ever seeing radiotherapy? Bet it’s the majority. Why aren’t we making noise about the 5-10% PFS benefits with appropriate use of cost effective RT? Is avoidance of toxic salvage therapy not a priority?”
Quoting the mentioned post by David Russler-Germain, Oncology Instructor at Siteman Cancer Center.
”CART cells are revolutionizing B-NHL treatment. But… Let’s not sweep under the rug:
(1) ~$400k product, ~$1M “total package”
(2) ~1/4 patients required ICU care
(3) Non-relapse mortality ~10%.
We need to acknowledge the downsides to make CART cells cheaper, faster, and safer.”
For the article click here.
Source: Jeff Ryckman/Twitter